CUMBERLAND® PHARMACE UTICALS Corporate Presentation Nasdaq CPIX Safe Harbor Statement This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the d ...

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q1 2021 Earnings Conference Call May 11, 2021 4:30 PM ET Corporate Participants Erin Gull - Corporate Relations Manager A. J. Kazimi - Chairman and Chief Executive Officer Marty Cearnal - President and Chief Commercial Officer Michael Bonner - Chief Financial Officer Conference Call Participants Operator Thank you for joining Cumberland Pharmaceuticals First Quarter 2021 Financial Report and Company Update. This call is being recorded at the company's request a ...

_________________________________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 of CUMBERLAND PHARMACEUTICALS INC. A Tennessee Corporation IRS Employer Identification No. 62-1765329 Commission file number 001-33637 2525 West End Avenue, Suite 950 Nashville, Tennessee 37203 (61 ...

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q4 2020 Earnings Conference Call March 9, 2021 4:30 PM ET Corporate Participants Erin Gull - Corporate Relations Manager A. J. Kazimi - Chairman and Chief Executive Officer Martin Cearnal - Executive Vice President and Chief Commercial Officer Michael Bonner - Senior Director Finance & Accounting, Chief Financial Officer Conference Call Participants Steve Kruger - Foresight Investment Operator Thank you for joining the Cumberland Pharmaceuticals Fourth Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 | --- | --- | |----------------------------------------------------------------------------------------|------------- ...

CUMBERLAND® PHARMACE UTICALS Corporate Presentation Nasdaq CPIX Safe Harbor Statement This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the d ...

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q3 2020 Earnings Conference Call November 10, 2020 4:30 PM ET Company Participants Erin Gull - Senior Corporate Relations Associate A. J. Kazimi - Founder, Chairman, President & CEO Martin Cearnal - EVP, Chief Commercial Officer & Director Michael Bonner - CFO and Senior Director, Finance & Accounting Conference Call Participants James Terwilliger - Paulson Investment Company Operator Thank you for joining the Cumberland Pharmaceuticals Third Quarter 2020 Finan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 | --- | --- | |---------------------------------------------------|------------------------------------------------------- ...

CUMBERLAND® PHARMACE UTICALS Corporate Presentation Nasdaq CPIX Safe Harbor Statement This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the d ...

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q2 2020 Earnings Conference Call August 11, 2020 4:30 PM ET Company Participants Erin Gull - IR A. J. Kazimi - CEO Marty Cearnal - Chief Commercial Officer Michael Bonner - CFO Conference Call Participants Andrew D'Silva - B. Riley FBR Operator Thanks to everyone participating on today’s call as Cumberland Pharmaceuticals provides Second Quarter 2020 Financial Report and Company Update. Please note that this call is being recorded and will be archived on Cumber ...